Schizophrenia: Drug discovery

Drug discovery for schizophrenia has long been based upon the dopamine hypothesis resulting in many compounds with similar mechanisms of action and which provide relief of the hallucinations and delusions of the disease. Unfortunately these ‘antipsychotic’ drugs have limited effectiveness against the negative symptoms (such as reduced motivation) and cognitive deficits (such as impaired flexibility of thinking and working memory); symptoms which are especially associated with impaired functional outcome.